23.2 Monitoring Eligibility, Safety and Products

Monitoring Eligibility, Safety and Products

Enrolling ineligible participants introduces confounding variables that compromise trial statistical power and exposes participants to unknown clinical risks.

• Primary Source Triangulation: The monitor verifies eligibility according to the monitoring plan, tracing relevant criteria to source evidence. Eligibility cannot be verified from a site-generated checklist alone; the CRA must trace each criterion back to certified primary source records (e.g., histology pathology reports confirming tumor staging, baseline laboratory chemistry panels, 12-lead ECG intervals, prior medical history notes from referring institutions).
• Prohibition of Protocol Waivers: Under modern GCP and regulatory standards, "protocol waivers" or retrospective eligibility exemptions granted by sponsors or medical monitors are strictly prohibited. Every subject must satisfy every protocol criterion exactly as written.

Source Data Verification (SDV) vs. Source Data Review (SDR)

A critical core competency tested on professional clinical research examinations is the conceptual and operational distinction between Source Data Verification and Source Data Review:

Safety Review and Serious Adverse Event (SAE) Reconciliation

Auditing participant safety is the monitor's paramount ethical duty:

• Adverse Event Log Review: The CRA audits clinic notes, nursing communication logs, vitals sheets, and laboratory panic values to identify potential adverse events that site personnel failed to record.
• Concomitant Medication Triangulation: The CRA cross-references newly prescribed or modified medications against the AE log. For example, if a participant's EMR reveals a new prescription for oral ciprofloxacin, the monitor investigates whether the site experienced and failed to report a urinary tract infection or respiratory infection as an adverse event.
• Immediate SAE Escalation (ICH E2A): Under E6(R3) and the trial safety plan, Serious Adverse Events (SAEs)—defined as any untoward medical occurrence resulting in death, life-threatening condition, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, or medically significant intervention—must be reported to the sponsor immediately, following the protocol and any permitted exceptions. The CRA verifies that SAE forms were transmitted immediately, that clinical details match hospital discharge summaries, that causality assessments were made by the appropriately qualified investigator/designee under applicable requirements, and that institutional IRB notification requirements were satisfied.

Investigational Product (IP) Accountability and Environmental Controls

Under ICH E6(R3), the CRA audits the physical and documented chain of custody of the investigational product:

• Storage Environmental Verification: Inspect the storage conditions and monitoring records against the product-specific instructions. Investigate undocumented excursions, protect affected stock from dispensing, and obtain sponsor evaluation/disposition. A generic ambient or refrigerated range cannot clear a particular batch.

• Physical Inventory Unit Counts: The CRA physically counts all unopened kits, partially used packages, and returned empty containers, comparing the physical count against the Master Drug Accountability Log (DAL) and individual Subject Dispensing Logs.

• Participant adherence: Compare dispensing, returns, medical holds and participant reports using the protocol's definition. Units dispensed minus units returned estimates use, not proven ingestion. Do not assume a universal 80–120% acceptable range.

Pharmacy and Ancillary Laboratory Inspection

The CRA inspects all support facilities contributing to trial data:

• Pharmacy Inspection: Verification of sterile preparation hoods, laminar flow certification dates, pharmacist training logs, access restriction (keycard/lock controls), and segregation of investigational supplies from commercial hospital stock.
• Laboratory Oversight: Auditing local clinical laboratories for appropriate laboratory quality/qualification evidence under applicable requirements. The CRA collects updated normal reference ranges signed and dated by the laboratory medical director.
• Biological Specimen Management: The CRA inspects $-20^\circ\text{C}$ and $-80^\circ\text{C}$ freezers housing pharmacokinetic (PK) and biomarker blood samples, verifying temperature logs, sample labeling, split-aliquot separation, and shipping manifests for central laboratory transport.

Official sources

Checked October 18, 2026: ICH E6(R3), Principles and Annex 1.